A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems.

Site-specific colon drug delivery is a practical approach for the treatment of local diseases of the colon with several advantages such as rapid onset of action and reduction of the dosage of the drug as well as minimization of harmful side effects. 5-aminosalicylic acid (5-ASA) is a drug of choice in the treatment of inflammatory bowel disease and colitis. For the efficient delivery of this drug, it is vital to prevent 5-ASA release in the upper part of the gastrointestinal tract and to promote its release in the proximal colon. Different approaches including chemical manipulation of drug molecule for production of prodrugs or modification of drug delivery systems using pH-dependent, time-dependent and/or bacterially biodegradable materials have been tried to optimize 5-ASA delivery to the colon. In the current review, the different strategies utilized in the design and development of an oral colonic delivery dosage form of 5-ASA are presented and discussed.

Gelatin hydrogel containing cerium oxide nanoparticles covered by interleukin-17 aptamar as an anti- inflammatory agent for brain inflammation.

The purpose of this study was to evaluate the anti-inflammatory property of gelatin hydrogel containing cerium oxide nanoparticles coated with interleukin-17 Aptemer ([CeON@IL-17]). Here, the brain inflammation model was induced by both proteolipid protein (PLP) and parathion. Then, the expression of some inflammatory genes and the serum level of related interleukins were evaluated. This study showed that the expression of IL-17, IL-10, and IL-6 genes and their serum levels were significantly decreased (P < .05) by administration of gelatin hydrogel containing [CeON@IL-17].